We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 13, 2020

Pazopanib vs Doxorubicin in Patients ≥60 Years With Metastatic Soft Tissue Sarcoma

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
J. Clin. Oncol 2020 Aug 24;[EPub Ahead of Print], V Grünwald, A Karch, M Schuler, P Schöffski, HG Kopp, S Bauer, B Kasper, LH Lindner, JM Chemnitz, M Crysandt, A Stein, B Steffen, S Richter, G Egerer, P Ivanyi, S Zimmermann, X Liu, A Kunitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading